Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 ...

Eli Lilly & Co. is bouncing back after a turbulent period, riding out volatility and posting a strong revenue increase in Q1 ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

A huge surge in Ireland's goods exports in the first quarter of 2025 was partially due to demand for weight loss drugs in the ...

Top marketing and advertising executives sat down with Variety in the C-Suite presented by Canva at Cannes to discuss their ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...